Ralf Guenzinger

Prof. Dr. Ralf Guenzinger


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2008 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
RGRalf Guenzinger
Ralf Guenzinger
WEWalter Benno Eichinger
Walter Benno Eichinger
IHIna Hettich
Ina Hettich
SBSabine Bleiziffer
Sabine Bleiziffer
DRDaniel Ruzicka
Daniel Ruzicka
RLRuediger Lange
Ruediger Lange

25 February 2008 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
RGRalf Guenzinger
Ralf Guenzinger
SWS.M. Wildhirt
S.M. Wildhirt
KVK. Voegele
K. Voegele
IWI. Wagner
I. Wagner
MSM. Schwaiger
M. Schwaiger
RLR. Lange
R. Lange
Background: Magnetic Resonance Imaging (MRI) and transthoracic echocardiography have been shown to be noninvasive highly sensitive diagnostic tools to identify changes in LV mass and volume. We therefore investigated the effects of mitral valve repair (MVR) on LV function parameters including ejection fraction (EF; %), indices of LV mass (LVMI; g/m2) and volume (LVEDVI, LVESVI; mL/m2) as detected by MRI and echocardiography. Methods: Eight consecutive patients (mean age 53.3 ± 10.0 years) with severe mitral regurgitation (MR; grade III–IV), normal LV function and sinus rhythm were included in this prospective study. Cine MRI and transthoracic M‐mode echocardiography were performed pre‐operatively, as well as 6 months post‐op, to identify changes in EF and in LV mass and volume. Data are given as mean ± standard deviation. Results: Post‐op MR was grade 0‐I in all patients. Early mortality and late mortality was 0%. EF by either method did not change significantly within the follow‐up period. A significant improvement of indices of LV mass and volume was detected by Cine MRI and echocardiography within 6 months following surgery (LVMIMRI: pre‐op: 76.3 ± 20.1 vs. post‐op: 66.5 ± 14.3, p < 0.05; LVMIEcho: pre‐op: 184.2 ± 38.1 vs. post‐op: 136.5 ± 28.4, p < 0.05. LVEDVIMRI: pre‐op: 119.3 ± 26.0 vs. post‐op: 75.4 ± 13.1, p < 0.05; LVEDVIEcho: pre‐op: 97.4 ± 28.8 vs. post‐op: 69.2 ± 13.1, p < 0.05. LVESVIMRI: pre‐op: 44.6 ± 12.0 vs. post‐op: 32.5 ± 9.5, p < 0.05; LVESVIEcho: pre‐op: 29.3 ± 8.3 vs. post‐op: 21.8 ± 4.6, p < 0.05). Conclusions: MRI and echocardiography show a significant reduction of LV volume and mass 6 months after MVR. The data show that for routine follow‐up transthoracic M‐mode echocardiography provides reliable information for the identification of LV mass and volume regression in patients after MVR.

1 July 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
RGRalf Guenzinger
Ralf Guenzinger
ESEike Philipp Schneider
Eike Philipp Schneider
TGThomas Guenther
Thomas Guenther
PWPetra Wolf
Petra Wolf
DMDomenico Mazzitelli
Domenico Mazzitelli
BVBernhard Voss
Bernhard Voss

Verified
Journal Article
Open access
PDF file
KSKonstantinos Sideris
Konstantinos Sideris
MBMelchior Burri
Melchior Burri
AMAntonia Mayr
Antonia Mayr
SVStephanie Voss
Stephanie Voss
KVKeti Vitanova
Keti Vitanova
RGRalf Guenzinger
Ralf Guenzinger
Objectives: The optimal surgical approach for the treatment of functional mitral regurgitation (FMR) remains controversial. Current guidelines suggest that the surgical approach has to be tailored to the individual patient. The aim of the present study was to clarify further aspects of this tailored treatment. Methods: From 01/2006 to 12/2015, 390 patients underwent mitral valve (MV) surgery for FMR (ischemic n = 241, non-ischemic n = 149) at our institution. A regression analysis was used to determine the effect of MV repair or replacement on survival. The patients were analyzed according to the etiology of the MR (ischemic or non-ischemic), different age groups (75 years), LV function, and LV dimensions, as well as the underlying heart rhythm. Results: The overall survival rates for the repair group at 1, 5, and 8 years were 86.1 ± 1.9%, 70.6 ± 2.6%, and 55.1 ± 3.1%, respectively. For the same intervals, the survival rates in patients who underwent MV replacement were 75.9 ± 4.5%, 58.6 ± 5.4%, and 40.9 ± 6.4%, respectively (p = 0.003). Patients younger than 65 years, with an ischemic etiology of FMR, poor ejection fraction ( 60mm), and presence of atrial fibrillation had significantly higher mortality rates after MV replacement (HR, 3.0; CI, 1.3–6.9; p = 0.007). Patients between 65 and 75 years of age had a higher risk of death when undergoing mitral valve replacement (HR, 1.7; CI, 1.0–2.8; p = 0.04). In patients older than 75 years, the surgical approach (MV repair or replacement) had no effect on postoperative survival (HR, 0.8; CI, 0.4–1.3; p = 0.003). Conclusions: Our data demonstrate that, in patients younger than 65 years, the treatment of choice for FMR should be MV repair. This advantage was even more evident in patients with an ischemic origin of MR, a poor ejection fraction, a severe LV dilatation, and atrial fibrillation.

16 November 2018 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
RGRalf Guenzinger
Ralf Guenzinger
RLRuediger S. Lange
Ruediger S. Lange
FRFriedrich-Christian Rieß
Friedrich-Christian Rieß
THThorsten Hanke
Thorsten Hanke
NBNicolas Bischoff
Nicolas Bischoff
SBSteven F. Bolling
Steven F. Bolling
Background Functional tricuspid regurgitation (FTR) secondary to left-sided heart disease may lead to poor quality of life and reduced long-term survival. This study evaluated clinical and functional outcomes of patients undergoing tricuspid valve (TV) repair using a rigid three-dimensional ring (Contour 3D, Medtronic) concomitant with another procedure. Methods From September 2011 to July 2015, 112 patients (mean age 70.9 ± 9.0 years) were enrolled at 10 centers in Europe, Israel, and the United States. Inclusion criteria were FTR ≥ moderate and/or tricuspid annular diameter (TAD) ≥ 40 mm. Echocardiography was planned before surgery and at discharge with echocardiographic and clinical follow-ups performed 6 months postoperatively. Results Three fourths (74.4%) of patients had higher than moderate TR. Mean TAD was 41.0 ± 7.3 mm; 61.7% of patients were in the New York Heart Association (NYHA) class III/IV. The most common concomitant procedure was mitral valve repair (57 patients, 53.3%). The 30-day mortality rate was 0.9% (n = 1). The mean EuroSCORE II was 8.9 ± 8.4% (median: 5.9%; interquartile range: 3.5–11.5%). The observed to expected ratio (O/E) based on the median was 0.1. Six deaths occurred during follow-up (three cardiac related). Mean implanted ring size was 30.3 ± 2.7. At 6 months, 94.4% of patients showed ≤ mild TR, and 92.0% were in NYHA class I/II (p < 0.001 vs baseline for both). Mean pressure gradient across the TV was 2.0 ± 1.1 mm Hg; leaflet coaptation length was 7.5 ± 3.3 mm. Conclusion The Contour 3D annuloplasty ring used for treatment of FTR substantially reduced TR for up to 6 postoperative months with low mean pressure gradients across the TV and significant improvement in NYHA class. Registration www.ClinicalTrials.gov, NCT01532921.

1 May 2004
Verified
Journal Article
Closed access
WEWalter B Eichinger
Walter B Eichinger
FBFlorian Botzenhardt
Florian Botzenhardt
RGRalf Guenzinger
Ralf Guenzinger
SBSabine Bleiziffer
Sabine Bleiziffer
AKAlexandra Keithahn
Alexandra Keithahn
RLRuediger Lange
Ruediger Lange